QGEN
Qiagen NV
NYSE: QGEN · HEALTHCARE · DIAGNOSTICS & RESEARCH
$32.63
-2.34% today
Updated 2026-06-05
Market cap
$7.64B
P/E ratio
18.91
P/S ratio
3.64x
EPS (TTM)
$1.96
Dividend yield
—
52W range
$33 – $58
Volume
2.1M
WallStSmart proprietary scores
61
out of 100
Grade: C+
Hold
Investment rating
2.7
Growth
F8.0
Quality
A7.0
Profitability
B+5.3
Valuation
C+5/9
Piotroski F-Score
Moderate
2.4
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$43.82
+34.29%
12-Month target
$39.87
+22.19%
Intrinsic (DCF)
$40.38
Margin of safety
-26.45%
2 Strong Buy6 Buy8 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $53.75M — positive
+ Debt/equity 0.49x — low leverage
Risks
- 26.45% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.14B | $1.97B | $1.98B | $2.09B | $2.10B |
| Net income | $423.21M | $341.30M | $83.59M | $424.88M | $68.04M |
| EPS | — | — | — | — | $1.96 |
| Free cash flow | $565.93M | $296.65M | $506.38M | $453.28M | $53.75M |
| Profit margin | 19.76% | 17.37% | 4.23% | 20.33% | 19.20% |
Peer comparison
Smart narrative
Qiagen NV trades at $32.63. representing a P/E of 18.91x trailing earnings. Our Smart Value Score of 61/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 2.40, it sits in the grey zone. TTM revenue stands at $2.10B. with profit margins at 19.20%. Our DCF model estimates intrinsic value at $40.38.
Frequently asked questions
What is Qiagen NV's stock price?
Qiagen NV (QGEN) trades at $32.63, on a P/E of 18.9x and a P/S of 3.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Qiagen NV overvalued?
Qiagen NV carries a Smart Value Score of 61/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $40.38 against the $32.63 price, so on cash flow terms the market is paying a premium for Qiagen NV's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Qiagen NV (QGEN)?
The 12-month analyst consensus target is $43.82, about 34.3% above the current $32.63. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Qiagen NV (QGEN)?
Our DCF model estimates intrinsic value at $40.38, a -26.4% margin of safety versus today's $32.63. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Qiagen NV's revenue?
Qiagen NV's trailing twelve-month revenue is $2.10B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Qiagen NV's Altman Z-Score is 2.40, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.64x
ROE12.07%
Beta0.66
50D MA$36.90
200D MA$44.17
Shares out0.21B
Float0.20B
Short ratio—
Avg volume2.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—